NRx Pharmaceuticals Publishes Shareholder Update Letter



Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup (p<0.001) RADNOR, Pa., Sept. 20, 2023 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)…

Leave a Reply